Response to ‘The use of online clearances in dialysis’  by Gross, Malte et al.
and abundant electron-dense mesangial deposits ultra-
structurally are consistent with HSP and not MPA. The
anti-neutrophil cytoplasm antibodies seronegativity is
an additional factor against MPA. (3) MPA and PN are
aggressive conditions that without treatment are associated
with high mortality and morbidity rates. Our patient was
treated with steroids (pulse methylprednisolone for 3 days
followed by oral prednisone) and angiotensin converting
enzyme inhibitor. He showed a significant decrease in
proteinuria and maintained normal renal function on
follow-up at 2 months, which would be unexpected if he
had MPA or PN. Thus, based on the clinical and pathologic
findings, we believe that the patient has HSP with multi-
organ involvement and not POS.
1. Shin J, Lee JS. Multiorgan involvement of vasculitis: Henoch-Scho¨nlein
purpura or polyangiitis overlap syndrome. Kidney Int 2008; 74: 828–829.
2. Watanabe K, Abe H, Mishima T et al. Polyangitis overlap syndrome: a fatal
case combined with adult Henoch Schonlein purpura and polyarteritis
nodosa. Pathol Int 2003; 53: 569–573.
3. Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and
prospective clinical experience. Am J Med 1986; 81: 79–85.
Meenakshi Zaidi1, Nandita Singh2, Mohammad Kamran2,
Naheed Ansari2, Samih H. Nasr3 and Anjali Acharya2
1Department of Medicine, Bronx VA Medical Center, North Central Bronx
Hospital, Bronx, New York, USA; 2Renal Division, Jacobi Medical Center,
Albert Einstein College of Medicine, Bronx, New York, USA and 3Department
of Pathology, College of Physicians and Surgeons, Columbia University,
New York, New York, USA
Correspondence: Anjali Acharya, Renal Division, Jacobi Medical Center,
Albert Einstein College of Medicine, 6E-23 B, Building 1, Bronx, New York
10461, USA. E-mail: anjali.acharya@nbhn.net
The use of online clearances in
dialysis
Kidney International (2008) 74, 829; doi:10.1038/ki.2008.273
To the Editor: Real-time measurement of dialysis efficacy is
sought by all practicing renal physicians in charge of dialysis
patients. Thus, we were very interested in the article by Gross
et al.,1 entitled ‘Online clearance measurement in high-
efficiency hemodiafiltration’. We were surprised to discover
that the paper reported the use of ionic dialysance to estimate
urea clearance, as we consider this method to be widely
accepted and that it was made commercially available quite a
long time ago.
Ionic dialysance as commented by Gross et al. was first
proposed to estimate urea clearance by Polaschegg2 and
Petitclerc et al.3 in 1993. Given the simplicity of the method,
many investigators have adopted it. We used ionic dialysance
for evaluating the efficacy of different types of online
hemodiafiltration after validating the results with blood
measurements of urea clearances in vivo and reported it in
the late nineties.4
Based on the accuracy of ionic dialysance in estimating
urea clearance, we further used this method to evaluate the
expected modifications in clearances by varying the convection
flows in pre- and post-dilutional high-efficiency hemodiafil-
tration. Our studies allowed us to define a simplified formula
to predict the clearance changes linked to convection. We
tested these formulas in vivo in dialysis patients and we
proposed their use in clinics. These studies were reported in
the journal in 2000.5
Although we do not know the reasons that led the authors
to overlook our reports when stating ‘a direct comparison of
ionic dialysance with blood-side clearance has been made
only in standard hemodialysis,’ we were disappointed to
discover that no new findings were presented in the current
paper. We would have been interested to know whether
the results of Gross et al. fit with the formulas we proposed in
our Technical Note of 2000 in Kidney International.5 This
would have represented a step forward in using ionic
dialysance in estimating the efficacy of high-efficiency
hemodiafiltration. Unfortunately, the current paper reports
a high rate of discarded measurements due to ‘technical
problems’ (48 out of 108 online measurements had to be
excluded for this reason), and adds little to the existing
literature.
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We have read with interest the letter submitted by Argile´s
et al.1 concerning our article on online clearance measure-
ment in high-efficiency hemodiafiltration.
Ionic dialysance measurement is a surrogate method to
evaluate urea clearance that has been extensively validated
in mainly diffusive hemodialysis. To perform in vivo
measurements of ionic dialysance, a transient conductivity
change of the dialysate is automatically applied and
dialysance is calculated from the time courses of the
conductivities at the dialysate inlet and outlet. In high-
efficiency hemodiafiltration, convection becomes the
predominant part of the cleansing process.
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We have extended the existing method of ionic
dialysance measurement in the diffusive regime to the
highly convective online hemodiafiltration regimen by
developing a method that is applicable to various modes of
substitution (post-, pre-, and mixed dilution). In contrast
to other theoretical methods, all required quantities can be
measured to a high precision without the knowledge of
blood and dialyzer properties. In our in vivo study, we have
validated our approach by taking the blood-side urea
clearance as a reference. We did not intend to do a
systematic analysis of the dependence of the dialysance on
the dialysis conditions.
In their in vitro experiment, Ficheux et al.2,3 evaluated
the impact of increasing ultrafiltration flow and varying
site of substitution on total ionic clearance. They nicely
illustrated that ionic dialysance is linearly correlated with
ultrafiltration flow. In contrast to our study, they did not
provide a technically feasible method to measure ionic
dialysance in vivo as their model either requires the
measurement of blood-side conductivity or the a priori
knowledge of the dialysance without online substitution.
In our study, 26 measurements have been omitted due
to errors in the sampling or processing of the correspond-
ing blood reference samples. During our experimental
study, size and shape of the transient conductivity change
were varied to determine their optimal values. From the
statistical analysis of the measurement, error threshold
values for these parameters were fixed. In 22 cases, the
conductivity change was suboptimal and the correspond-
ing measurements were excluded from the final analysis.
No individual measurements were excluded a posteriori as
statistical outliers.
We conclude that in contrast to what the authors of this
letter claim, our modeling approach is quite original. It
allows the determination of the ionic dialysis in online
hemodiafiltration treatments by measurements on the
dialysate side alone. This approach provides a safe and
reliable tool to evaluate routinely in clinic the dialysis dose
delivered by online HDF.
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To the Editor: I read with interest the study by Reungjui
et al.1,2 and the accompanied editorial published in the same
issue of Kidney International. The study by Reungjui et al.
included 20–24 rats divided into four groups, with two of
them being subjected to thiazide diuretics. The authors
convincingly show that low kidney function and glomerular
and tubular injury manifest more commonly in thiazide-
treated rats, an effect that cannot be explained by
hypokalemia alone. Various credible explanations were also
provided and are all well taken. However, in the conclusion
section as well as in the editorial that accompanied this
article, the authors make a connection between the
pathological findings in rats and the results of various
clinical hypertensive studies done in humans. Although I do
not disagree or agree with the authors’ interpretations and
arguments regarding the design and outcome of these cited
clinical trials, I find it very puzzling to make a link between
pathological findings in rats taking thiazide diuretics and
clinical studies that used thiazides in humans. Current
knowledge indicates that rat kidneys differ not only from
humans but there is also intraspecies variability.3,4 A few
other questions come to mind. Assuming that the rats
actually drank all the thiazide-loaded water and accordingly
received 1.5–1.75 mg thiazide/day, how does this dose
translate to clinical practice or to the dose used in the
ALLHAT or AASK trials? What is the equivalent of 20 weeks
of rat age in human life? Can the same findings be
reproduced if another rat species was used?
Basic science research continues to be the best tool to
build breakthrough clinical research, but until studies
dedicated to examine the effect of chronic thiazide use on
histological findings and/or kidney function in humans
become available, I think extrapolating from animal studies
risks unwarranted changes in clinical practices and public
confusion.
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